REGENERON PHARMACEUTICALS, INC.·4

Dec 11, 4:23 PM ET

SCHLEIFER LEONARD S 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Dec 11, 2025

Insider Transaction Report

Form 4
Period: 2025-12-09
SCHLEIFER LEONARD S
DirectorCEO and President10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-09$555.67/sh+172,723$95,976,989369,668 total
  • Tax Payment

    Common Stock

    2025-12-09$701.51/sh155,145$108,835,769214,523 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2025-12-09172,7230 total
    Exercise: $555.67Exp: 2025-12-16Common Stock (172,723 underlying)
Holdings
  • Common Stock

    (indirect: By 2024 GRAT)
    127,484
  • Common Stock

    (indirect: By 2025 GRAT)
    300,000
  • Common Stock

    (indirect: By 401(k))
    5,989
  • Common Stock

    (indirect: By Trust)
    39,985
Footnotes (1)
  • [F1]The stock option award vested in four equal annual installments, commencing one year after the date of grant.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT